Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Warren Buffett Can’t Get Enough of DaVita

Yesterday, Warren Buffett’s Berkshire Hathaway publicly disclosed a new Form 4 filing, in which it revealed that it had increased its exposure at DaVita HealthCare Partners Inc (NYSE:DVA). Berkshire purchased just under 3.7 million shares, bringing its total holdings in the healthcare company to 35.1 million shares. The shares were purchased at prices ranging from $53.24 to $55.98, and with this latest acquisition, Berkshire Hathaway now owns approximately 16.5% of DaVita, one of the nation’s leading kidney care specialists.

Warren Buffett portrait

The purchase of DaVita shares comes just a few days after the firm announced its third quarter results. During the conference call the company’s CEO made some rather dramatic statements such as: “I want to remind you that if there are significant cuts, we will be forced to close a number of centers.”

The statement continued emphasizing the difficulties 2014 will bring, as the following excerpt explains: “In addition to the Medicare cuts that may happen, we also have potential hits due to increased commercial rate pressure and the potential impact of the exchanges, and so we will be looking to do some expense pruning wherever we can, although we cannot put a number on that at this time.

But why would Warren Buffett add to its holdings of DaVita with such a grim outlook?

The answer is actually quite simple: long-term investment. Since share prices dropped around 4% following the conference call, Berkshire Hathaway took advantage of the situation to increase its holdings at a reduced price. The uncertainties DaVita is facing are short-term, while its long-term projections remain intact, thus Berkshire’s acquisition makes sense.

Apart from Berkshire Hathaway, which is by far the firm with the largest holdings in DaVita (of those we track), Alan Fournier’s Pennant Capital Management has a large position here too. Other hedge funds, such as William B. Gray’s Orbis Investment Management, D.E. Shaw, and Jeffrey Gates’ Gates Capital Management, hold more than 1 million shares of common stock each.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!